Pharmacyclics’ Q4 2013 earnings surge on Imbruvica’s success
The Sunnyvale-based company’s strong earnings were as expected, given the promising developments since the third quarter, including the FDA’s approval of its drug, Imbruvica, for treatment of those with mantle cell lymphoma